2 / 7
Page 44
allied
academies
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Statement of the Problem:
Africa currently produces only 1%
of its vaccine needs, a situation that exposes African countries
to a high risk of epidemics and pandemics, weakened national
security, poor emergency preparedness and poor sustainability
and supply assurance of vaccines. AVMI commissioned the
Vaccine Manufacturing and Procurement in Africa (VMPA)
study to assess the feasibility of establishing sustainable
vaccine manufacturing capacity in Africa.
Methodology:
This analytical assessment of vaccine
manufacturing capacity and procurement mechanisms in
Africa was designed to answer four key questions related
to understanding the vaccine market dynamics in Africa, the
vaccine procurement & financing mechanisms, the technical
feasibility of establishing sustainable vaccine manufacturing
capacity in Africa, and the cost drivers and funding mechanisms
in establishing sustainable vaccine manufacturing in Africa.
The methodology combined field observations, quantitative
and qualitative approaches, desk review, questionnaires and
interviews withmanufacturers, resource persons and experts as
well as regular consultation with the VMPA Study management
team and an expert Strategic Advisory Group.
Findings:
In 2013, Africa vaccine market was approximately
5.5% of the global vaccine market, with an ever-increasing
demand in terms of number of doses of vaccine and vaccine
types. In 45 of the 54 African countries, UNICEF is the
predominant procurer; the percentage of UNICEF vaccine sales
in Africa compared to the total UNICEF vaccine sales globally
is around 60%. Only eight companies in Africa have existing
or potential vaccine manufacturing capacities, only one of
which currently exports a WHO prequalified vaccine (Yellow
Fever). There are huge obstacles for establishing sustainable
vaccine manufacturing capacity in Africa, including industrial
and commercial competition for routine vaccines, scientific,
technical, managerial and financial challenges, compounded
by the lack of an enabling ecosystem in most African countries.
Conclusion & Significance:
Current vaccine supply in Africa is
heavily influenced by funding sources and global community
policies and incentives. While the potential for developing
vaccine manufacturing capacity in Africa exists, current
procurement and related practices could impede the utilization
of any African manufactured vaccines and therefore require
in-depth consideration for sustainability of local vaccine
production. Active intervention to establish a conducive
business environment is required for the development of a
more comprehensive and sustainable vaccine manufacturing
industry in Africa
e:
chidinweneka@hotmail.comGrowing sustainable and resilient human vaccines development and manufacturing capabilities in
Africa – challenges and opportunities
Chidi V Nweneka, Patrick Tippoo, Ebrahim Mohamed
and
William Ampofo
AVMI, South Africa